Photosensitizer Drugs Market: Introduction
- Photosensitizer drugs or photosensitizing agents are used in the photodynamic therapy (PDT) for the treatment of cancer. These agents are exposed to a specific wavelength of light to produce active form of oxygen that kills nearby cancer cells. Various forms of photosensitizer drugs includes porphyrin derivatives, Aminolevulinic acid (ALA), chlorines, and others.
Get a Glimpse of the In-Depth Analysis through our Comprehensive Photosensitizer Drugs Market Brochure
- First generation photosensitizers, porphyrin derivative (PD) are effective for treating brain, lung, laryngeal, gastric, skin, and esophageal carcinomas to a certain degree. Photosensitizing agent called porfimer sodium, or Photofrin, is a U.S. FDA approved drug used in PDT for the treatment of esophageal cancer and non-small cell lung cancer.
- Second generation photosensitizers are based on porphyrin structure such as benzoporphyrins, texaphyrins, purpurins, naphthalocyanines, and phthalocyanines
- Another commonly used photosensitizer is 5-aminolevulinic acid (ALA), which is majorly used for oral leukoplakia, owing to the benefits of low-light dose
- Photosensitizers, such as mono-aspartyl chlorine e6 (NPe6), temoporfin, and hexylpyropheophorbide (HPPH), are based on the chlorine structure
Request COVID Analysis on Photosensitizer Drugs Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74795
Key Drivers of Global Photosensitizer Drugs Market
- Increase in prevalence of cancers and rise in the burden of dermatology disorders are key factors projected to boost the global photosensitizer drugs market during the forecast period
- According to the American Society of Clinical Oncology (ASCO), head and neck cancer accounted for nearly 4% of all cancers in the U.S. in 2017. The report indicated that approximately 65,000 individuals would develop head and neck cancer. This is anticipated to increase the demand for photosensitizer drugs in the near future.
- Skin diseases are considered to be significantly common and rank fourth among the most common illnesses globally
- According to the World Health Organization (WHO), one in every three cancers diagnosed is skin cancer and according to Skin Cancer Foundation Statistics, one in every five Americans would develop skin cancer in their lifetime
- Baby boomer population susceptible to a range of cancers and skin diseases is expected to drive the demand for photosensitizer drugs during the forecast period
Pre Book Photosensitizer Drugs Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=74795<ype=S
North America to Dominate Global Photosensitizer Drugs Market
- Rise in prevalence of skin disorders, such as acne, psoriasis, actinic keratosis, increase in prevalence of cancers, and surge in the number of cosmetologists using PDT, are likely to propel the demand for photosensitizer drugs in the region
- Acne is considered to be one of the most common skin conditions in the U.S., which affects over 50 million people every year. Its prevalence is known to be higher in women, affecting over 15% of the total adult women population.
- Psoriasis is known to affect over 7.5 million people in the U.S. each year, with higher prevalence in population aged between 45 years and 64 years
- This significant rise in the prevalence of skin diseases and economic burden of these diseases create demand for cost-effective modes of treatment. This, in turn, is boosting the growth of the global photosensitizer drugs market.
- The photosensitizer drugs market in the U.K. is anticipated to grow at a rapid pace, owing to approval of drugs indicated for cancer, increase in R&D expenditure on oncology, and rapid expansion of the pharmaceutical industry in the country
- Growing attention toward new anti-cancer therapies is also an important factor that is likely to drive the global market during the forecast period
- In October 2019, Theralase Technologies Inc. was granted a European Patent for their anti-cancer light-activated photodynamic compounds (PDCs)
- Rise in the burden of skin disorders, including acne, psoriasis, and presence of a large baby boomer population, which increases the risk of cancer in developing countries, such as India and China, are key factors augmenting the photosensitizer drugs market in Asia Pacific
Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Photosensitizer Drugs Market Report
Key Players Operating in Global Photosensitizer Drugs Market
Major players operating in the global photosensitizer drugs market are:
- Galderma laboratories
- BIOFRONTERA AG
- Sun Pharmaceutical Industries Ltd
- LUMIBIRD group (Quantel Medical)
- Theralase Technologies Inc
- Quest PharmaTech Inc.
- Modulight Sorin
- Excel Lasers Limited
Trending Reports of Transparency Market Research –
Minimally Invasive Surgery Market –
Nurse Call Systems Market –
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com
